PATIENT FOCUSED DRUG DEVELOPMENT MEETING

Slides:

Advertisements

Similar presentations

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.

Advertisements

Susan Boynton, VP, Global Regulatory Affairs, Shire

Engaging Patients and Other Stakeholders in Clinical Research

Highly Specialised Technologies Evaluations

Clinical Trials Medical Interventions

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

WELCOME TO THE NEW YORK TSC CONFERENCE May 5, 2013.

Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

Sociology 3322a. “…the systematic assessment of the operation and/or outcomes of a program or policy, compared to a set of explicit or implicit standards.

ND Early Childhood Outcomes Process Nancy Skorheim – ND Department of Public Instruction, Office of Special Education.

Edmonton Public Schools Sustainability Review & School Closure Process johnstonresearch.

PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.

Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.

The Engagement Cycle : engaging with patients and public throughout the commissioning process In collaboration with NHS Institute and DH.

Patient Engagement in Drug Development: Experiences, Good Practices and Lessons Learned Lana Skirboll VP Science Policy Sanofi October 28, 2016, National.

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

CLINICAL TRIALS.

CIPN: Considerations for Drug Development

Strengthening the Medical Device Clinical Trial Enterprise

Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.

Introducing ASPR’s Coalition Surge Tool

The CRT of EFS Where We’ve Been and Where We’re Going

All participants will be muted as they enter the webinar.

Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S

School Community Council Roles and Responsibilities

Patient Focused Drug Development An FDA Perspective

Presentation Developed for the Academy of Managed Care Pharmacy

Research Questions Does integration of behavioral health and primary care services, compared to simple co-location, improve patient-centered outcomes in.

Balancing Pre and Postmarket Requirements Different Scenarios

DIA Clinical Safety and Pharmacovigilance Community

The FDA Early Feasibility Study Pilot and the Innovation Pathway

The Patient Experience With Systemic Lupus Erythematosus

First-in-Man, First In The USA: What’s The Difference?

Clinical Trials Medical Interventions

Myotonic Dystrophy Foundation

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

FACILITATING DRUG DEVELOPMENT FOR TUBEROUS SCLEROSIS COMPLEX

FDA-CDRH in the Next Decade A Vision for Change

Introducing ASPR’s Coalition Surge Tool

Here Is Some More About Drug Addiction Treatment

Research Overview Jacqueline French, MD Chief Scientific Officer

MULTIMORBIDITY: THE MOST COMMON CHRONIC CONDITION

Changing the Game for Sjögren's Patients

Positive Impacts of Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials* SPECIFIC BENEFITS SHORT-TERM MEDIUM-TERM LONG-TERM.

Clinical Trials.

Presentation Developed for the Academy of Managed Care Pharmacy

National Association of Medicaid Director’s Fall Conference

September 7, 2018 Courtney Baird, MS

Streamlining IRB Procedures for Expanded Access

Tuberous Sclerosis Complex Fundamental Concepts in Diagnosis and Management.

Writing Cochrane Protocol Cochrane Thailand Workshop 2017

Informed Consent (SBER)

Colorado’s Essential Health Benefit Benchmark Plan

Active Learning Network of Care Centers Working on Outcome Improvement Key Driver Diagram: Jan – Dec 2019 KEY DRIVERS CHANGES & INTERVENTIONS Efficient.

Emotional Health and Wellbeing through Physical Activity

Opportunity Nottingham in partnership with NCVS

An Update of COSO’s Internal Control–Integrated Framework

Patient Involvement in the Development and Use of Safe Medicines Introductory Section – Concepts to Consider CIOMS XI WG Second Meeting October 23-24,

Module 5: Formulating Research Questions

A PILOT STUDY EXAMINING CRITERIA USED TO SELECT DRUGS FOR HOSPITAL, PROVINCIAL AND NATIONAL FORMULARIES Robertson J, Newby DA, Pillay T, Walkom EJ The.

Information Pack Advice Leading to Public Health Advancement

Why NIH Clinical Research Matters

Presentation Developed for the Academy of Managed Care Pharmacy

Differentiating learning outcomes using feedforward

Establishing HTA Impact Evaluation From Day One Ruth Louise Poole

An Agency Perspective on Plain Language Summaries of Publications

Presentation transcript:

PATIENT FOCUSED DRUG DEVELOPMENT MEETING Gabrielle Rushing March 2nd, 2017

The fda wants to understand the patient perspective Providing the FDA an insight into daily living for individuals affected by TSC/LAM The TS Alliance is sponsoring an externally-led PFDD just prior to this year’s International Research Conference on TSC and LAM Wednesday, June 21st, 2017 8:30 AM – 4:30 PM Hyatt Regency on Capitol Hill, Washington DC Both the patient perspective and the family/caregiver perspective FDA sponsors 25 of these meetings over a 5 year period (2012-2017)

Who will be there? Individuals with TSC and/or LAM or their caregivers Invited panel members Attending in person Participating via live web broadcast FDA Staff Office of New Drugs Office of Health and Constituent Affairs Office of Orphan Products Development Center for Drug Evaluation and Research

What will be discussed? The PFDD will be separated into two parts: Epilepsy AML/LAM Within these topics, we will address: Impact of these symptoms on an individual’s daily life Most impactful treatments How well treatment is working The TS Alliance has given out a survey to collect a variety of comments and input on priorities from the TSC community and will continue to collect more responses. This Tuesday, we met with a small group to discuss what types of questions should be addressed at the meeting and so that we can truly focus on what affects patient’s and caregivers day to day.

EXAMPLE SURVEY Questions Which 1-3 symptoms have the most significant impact on life? Are there specific activities that are important that those affected cannot do at all/as fully as they would like because of their condition? How have their symptoms changed over time? What makes them better or worse? How are you currently treating the symptoms? Has the treatment regimen changed over time? How well do these treatments improve the ability to perform specific activities? What are the downsides to current treatments? Pre-specified answers on polling questions.

How will this be helpful to affected individuals? The “Voice of the Patient” (VOP) report Summary of PFDD findings Submitted to the FDA Available online Informs the FDA’s decisions on drug development and review of market applications This is a very important consideration as many clinical trials do not capture the effects on how patient’s feel or function day to day as a whole (example: one of the current epilepsy treatments, affinitor, although effective has adverse effects).

PFDD design Introduction to TSC and treatments Session 1: Epilepsy in infants with TSC Session 2: Angiomyolipomas (AML) and lymphangioleiomyomatosis (LAM) in adults with TSC Topic 1: Living with TSC (disease symptoms/daily impacts that matter most to patients) Panel discussion and facilitated large group discussion Topic 2: Current & future approaches to treating TSC

What happens after the meeting? Webcast recording Downloadable transcript The Voice of the Patient Report

How will this help the development of new therapies? FDA Risk-Benefit Analysis Analysis of condition and current treatment options Potential ‘early intervention’ studies to potentially prevent specific manifestations of TSC Basic structure of a benefit-risk framework that includes the following categorization of key decision factors: Analysis of Condition, Current Treatment Options, Benefit, Risk, and Risk Management. Analysis of Condition and Current Treatment Options provide a summary and assessment of the severity of the condition that the product is intended to treat and other therapies available to treat the condition. This represents the context of the decision that can provide useful information for weighing the benefits and risks of the drug under review.

Example: early intervention clinical trial Preventing Epilepsy using Vigabatrin in Infants with Tuberous Sclerosis Complex (PREVeNT) trial- began December 2016 Goal: To test whether early treatment with Vigabatrin before the onset of seizures in TSC infants having an abnormal EEG biomarker can prevent epilepsy and improve developmental outcomes

Questions?